Adicet bio appoints michael grissinger to the board of directors

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the appointment of michael grissinger to its board of directors. mr. grissinger brings more than four decades of experience in business development, strategy, and m&a leadership roles at global pharmaceutical companies. “we are honored to welcome michael t.
ACET Ratings Summary
ACET Quant Ranking